Modulating Aβ Fibrillogenesis with 'Trojan' peptides.

Neuropeptides
Gaurav PandeyVibin Ramakrishnan

Abstract

Abnormal aggregation of beta-amyloid (Aβ) peptide into amyloid plaques in the brain has been identified as one of the key factors in instigating AD pathogenesis. Inhibition of Aβ aggregation can be an important therapeutic strategy in disease management. In this work, we demonstrate the application of structure-based design of short peptides ('trojan peptides'), intended to intervene in the aggregation of the core recognition domain of amyloid-beta peptide, a known malefactor in Alzheimer's disease. The modulatory effect of trojan peptides has been assessed using ThT fluorescence assay, FETEM imaging, IR, and toxicity assays on model neuronal cell lines. Experimental results suggest that designed trojan peptides could impede the aggregation of the core amyloid fibril forming segment of Aβ peptide, arrest the formation of toxic fibrillar assemblies, and reduce cytotoxicity of the neuronal cell lines.

Citations

Nov 11, 2021·Journal of Biochemical and Molecular Toxicology·Komal JabeenMuhammad Sajid Hamid Akash

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alzheimer's Disease: Neuroimaging

Neuroimaging can help identify pathological hallmarks of Alzheimer's disease (AD). Here is the latest research on neuroimaging modalities, including magnetic resonance imaging and positron emission tomography, in AD.

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.

Related Papers

Current Medicinal Chemistry
Ana-Maria Chiorcea-PaquimAna Maria Oliveira-Brett
Drug Discovery Today
M Habeck
Canadian Medical Association Journal
H D Covvey, N McAlister
Canadian Medical Association Journal
© 2021 Meta ULC. All rights reserved